PepGen Inc. - Common Stock (PEPG)
5.2497
+2.5897 (97.36%)
NASDAQ · Last Trade: Sep 25th, 11:20 AM EDT
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.
Via Chartmill · September 25, 2025
PepGen Stock More Than Doubles On Thursday – Check Out The New Price Targets On Wall Streetstocktwits.com
Via Stocktwits · September 25, 2025
U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 1% on Thursday. Following the market opening Thursday, the Dow traded down 0.50% to 45,889.75 while the NASDAQ fell 1.38% to 22,187.39. The S&P 500 also fell, dropping, 0.94% to 6,575.35.
Via Benzinga · September 25, 2025
PepGen Inc. (NASDAQ: PEPG) stock is skyrocketing on Thursday, with a session volume of 53.04 million compared to the average volume of 943.2 thousand as per data from Benzinga Pro.
Via Benzinga · September 25, 2025
The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Via Chartmill · September 25, 2025
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via Benzinga · September 25, 2025
Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session. The market value of their outstanding shares is at $87.2 million.
Via Benzinga · September 25, 2025
Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced the launch of an underwritten public offering of common stock and pre-funded warrants.
Via Benzinga · September 25, 2025
With U.S. stock futures trading mixed this morning on Thursday, some of the stocks that may grab investor focus today are as follows:
Via Benzinga · September 25, 2025
PepGen shares surged 119.55% after announcing an underwritten public offering, with proceeds to support clinical trials for neuromuscular diseases.
Via Benzinga · September 25, 2025
Via Benzinga · September 24, 2025
After the closing bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Via Chartmill · September 24, 2025
Via Benzinga · September 24, 2025
Via Benzinga · September 10, 2025
Via Benzinga · September 9, 2025
PepGen reported a Q2 2025 net loss of $23.1M, beating EPS estimates. Clinical progress in DM1 trials and stable cash position highlight the update. Stock shows mixed performance amid legal scrutiny.
Via Chartmill · August 7, 2025
Via Benzinga · July 11, 2025
Wondering what's happening in Tuesday's pre-market session? Find an overview in this article.
Via Chartmill · July 8, 2025
Via Benzinga · July 8, 2025

Via Benzinga · June 6, 2025

PepGen ends Duchenne drug program after weak Phase 2 results, pivots to DM1 treatment showing early signs of splicing correction and safety.
Via Benzinga · May 29, 2025
Via Benzinga · May 16, 2025
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via Chartmill · April 22, 2025

PepGen halts its Phase 2 CONNECT2 trial for PGN-EDO51 in DMD to assess 10 mg/kg cohort data, while advancing FREEDOM-DM1 studies in myotonic dystrophy.
Via Benzinga · March 4, 2025